| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL1a2 |
| Uniprot No | P08123 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1133-1366aa |
| 氨基酸序列 | YEVDATLKSLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDP NQGCTMDAIKVYCDFSTGETCIRAQPENIPAKNWYRSSKDKKHVWLGETI NAGSQFEYNVEGVTSKEMATQLAFMRLLANYASQNITYHCKNSIAYMDEE TGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEYK TNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL1A2重组蛋白的3篇参考文献及简要摘要：
1. **文献名称**：*Recombinant expression and characterization of human collagen α2(I) chain in Escherichia coli*
**作者**：Smith J, et al.
**摘要**：研究利用大肠杆菌系统高效表达人源COL1A2重组蛋白，优化纯化工艺并验证其形成三螺旋结构的能力，为大规模生产提供基础。
2. **文献名称**：*Functional analysis of COL1A2 mutations in osteogenesis imperfecta using recombinant collagen models*
**作者**：Lee S, et al.
**摘要**：通过重组COL1A2蛋白模拟成骨不全症相关突变，揭示突变导致胶原纤维组装缺陷及力学性能下降的分子机制。
3. **文献名称**：*Biomimetic collagen matrices based on recombinant COL1A2 for cartilage regeneration*
**作者**：Zhang Y, et al.
**摘要**：开发基于重组COL1A2的仿生胶原支架，证明其可促进软骨细胞黏附、增殖及细胞外基质分泌，在组织修复中具应用潜力。
(注：以上文献为示例，实际引用需以真实发表文献为准。)
**Background of COL1a2 Recombinant Protein**
The COL1A2 gene encodes the alpha-2 chain of type I collagen, a major structural protein in the extracellular matrix (ECM) of connective tissues, including skin, bone, tendons, and ligaments. Type I collagen consists of two alpha-1 chains (COL1A1) and one alpha-2 chain (COL1A2), forming a triple-helix structure critical for tissue strength and integrity. COL1A2 contributes to fibril assembly, mechanical stability, and interactions with other ECM components.
Mutations in COL1A2 are linked to osteogenesis imperfecta (brittle bone disease), Ehlers-Danlos syndrome, and other connective tissue disorders. Recombinant COL1a2 protein is produced in vitro using expression systems (e.g., mammalian cells, bacteria, or yeast) to study collagen biosynthesis, disease mechanisms, or therapeutic applications. Its production often requires post-translational modifications (e.g., hydroxylation of proline/lysine) to ensure proper folding and functionality.
In research, recombinant COL1a2 aids in modeling collagen-related pathologies, screening drugs targeting ECM disorders, or developing biomaterials for tissue engineering. It also serves as a reference standard in diagnostics. Challenges include maintaining the protein’s native structure and stability outside physiological conditions. Advances in recombinant technology and 3D cell culture systems have improved its utility in regenerative medicine and personalized therapeutics.
Overall, COL1a2 recombinant protein is a vital tool for understanding collagen biology and translating insights into clinical solutions for connective tissue diseases.
×
